// App-Quantinova.ai

7531 : A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.

Researchers

Presenter

  • Luana Calabr

Principal Investigators

  • Aldo Morra

  • Riccardo Danielli

  • Diana Giannarelli

  • Maresa Altomonte

  • Anna Maria Di Giacomo

  • Michele Maio

  • Ester Fonsatti

  • Ornella Cutaia

  • Carolina Fazio

Medical Centers

  • Department of Radiology, Euganea Medica Diagnostic Center, Padua, Italy

  • Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, ItalyUniversity Hospital of Siena, Istituto Toscano Tumori, Siena, ItalyRegina Elena National Cancer Institute, Rome, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mesothelioma

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Ticilimumab

Outcome

  • Positive

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01655888

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved